191 related articles for article (PubMed ID: 1362408)
1. Expression of the ret proto-oncogene in human medullary thyroid carcinomas and pheochromocytomas of MEN 2A.
Miya A; Yamamoto M; Morimoto H; Tanaka N; Shin E; Karakawa K; Toyoshima K; Ishizaka Y; Mori T; Takai S
Henry Ford Hosp Med J; 1992; 40(3-4):215-9. PubMed ID: 1362408
[TBL] [Abstract][Full Text] [Related]
2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
3. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas.
Santoro M; Rosati R; Grieco M; Berlingieri MT; D'Amato GL; de Franciscis V; Fusco A
Oncogene; 1990 Oct; 5(10):1595-8. PubMed ID: 1701232
[TBL] [Abstract][Full Text] [Related]
4. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.
Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A
Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697
[TBL] [Abstract][Full Text] [Related]
5. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
Mulligan LM; Kwok JB; Healey CS; Elsdon MJ; Eng C; Gardner E; Love DR; Mole SE; Moore JK; Papi L
Nature; 1993 Jun; 363(6428):458-60. PubMed ID: 8099202
[TBL] [Abstract][Full Text] [Related]
6. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
7. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.
Eng C; Foster KA; Healey CS; Houghton C; Gayther SA; Mulligan LM; Ponder BA
Br J Cancer; 1996 Aug; 74(3):339-41. PubMed ID: 8695346
[TBL] [Abstract][Full Text] [Related]
9. Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A.
Quadro L; Panariello L; Salvatore D; Carlomagno F; Del Prete M; Nunziata V; Colantuoni V; Di Giovanni G; Brandi ML; Mannelli M
J Clin Endocrinol Metab; 1994 Aug; 79(2):590-4. PubMed ID: 7913936
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
[TBL] [Abstract][Full Text] [Related]
11. Identification and analysis of the ret proto-oncogene promoter region in neuroblastoma cell lines and medullary thyroid carcinomas from MEN2A patients.
Itoh F; Ishizaka Y; Tahira T; Yamamoto M; Miya A; Imai K; Yachi A; Takai S; Sugimura T; Nagao M
Oncogene; 1992 Jun; 7(6):1201-6. PubMed ID: 1350670
[TBL] [Abstract][Full Text] [Related]
12. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma.
Kimura T; Yoshimoto K; Yokogoshi Y; Saito S
Endocr J; 1995 Aug; 42(4):517-25. PubMed ID: 8556059
[TBL] [Abstract][Full Text] [Related]
14. The RET proto-oncogene in sporadic pheochromocytomas.
Takaya K; Yoshimasa T; Arai H; Tamura N; Miyamoto Y; Itoh H; Nakao K
Intern Med; 1996 Jun; 35(6):449-52. PubMed ID: 8835594
[TBL] [Abstract][Full Text] [Related]
15. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin.
Takaya K; Yoshimasa T; Arai H; Tamura N; Miyamoto Y; Itoh H; Nakao K
J Mol Med (Berl); 1996 Oct; 74(10):617-21. PubMed ID: 8912182
[TBL] [Abstract][Full Text] [Related]
16. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation.
Nilsson O; Tisell LE; Jansson S; Ahlman H; Gimm O; Eng C
JAMA; 1999 May; 281(17):1587-8. PubMed ID: 10235148
[No Abstract] [Full Text] [Related]
17. Genetic aberrance of sporadic MEN 2A component tumours: analysis of RET.
Cho NH; Lee HW; Lim SY; Kang S; Jung WY; Park CS
Pathology; 2005 Feb; 37(1):10-3. PubMed ID: 15875728
[TBL] [Abstract][Full Text] [Related]
18. Expression of the ret proto-oncogene in phaeochromocytoma. An in situ hybridization and northern blot study.
Matias-Guiu X; Colomer A; Mato E; Cuatrecasas M; Komminoth P; Prat J; Wolfe H
J Pathol; 1995 May; 176(1):63-8. PubMed ID: 7616358
[TBL] [Abstract][Full Text] [Related]
19. RET proto-oncogene mutations and rearrangements in endocrine diseases.
Lloyd RV
Am J Pathol; 1995 Dec; 147(6):1539-44. PubMed ID: 7495277
[No Abstract] [Full Text] [Related]
20. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
Hofstra RM; Landsvater RM; Ceccherini I; Stulp RP; Stelwagen T; Luo Y; Pasini B; Höppener JW; van Amstel HK; Romeo G
Nature; 1994 Jan; 367(6461):375-6. PubMed ID: 7906866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
